EAS Newsletter July 16, 2024
Society:
Don’t let this opportunity pass you by. Apply for an EAS Competitive grant
Don’t let this opportunity pass you by! Submit your application for an EAS Competitive grant by September 13, 2024. Before you apply, make sure to thoroughly review the eligibility criteria, funding terms, and conditions listed below. Take this chance to boost your career with EAS!
Apply for Competitive grants for EAS members 2024Education:
EAS-LatAm webinar series will continue. Be sure to register for the third webinar!
The atherogenic role of triglyceride-rich lipoproteins (TRL) and whether mild or moderate increases warrant pharmacological intervention have long been subjects of debate. Despite gaps in our understanding of the mechanisms behind residual risk, TRLs are thought to play a significant role. Improving our understanding of TRL’s effects on the atherosclerotic process is essential for advancing our management of hypertriglyceridemia.
Join us for the third webinar in our joint EAS-LatAm series to explore this topic in depth. Register now!
To the registration pageEducation:
Gene therapy in lipid metabolism and CVD discussed by Prof. Sekar Kathiresan
Sekar Kathiresan is the Chief Executive Officer and founder of Verve Therapeutics, US. Previously, he was a Professor of Medicine at Harvard Medical School and the Director of the Center for Genomic Medicine in Boston, USA.
As a leading researcher in the field of the genetic background of cardiovascular disease, his work has enhanced the understanding of the inherited basis for blood lipids and myocardial infarction. In recent years, gene therapy has become a reality for several monogenic diseases.
In this lecture, he will explore the recent advances in gene therapy for treating dyslipidemia to prevent heart attacks.
To the Open Lecture by Prof Sekar Kathiresan